A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201

被引：38
|
作者：
Loehrer, P. J., Sr.
Powell, M. E.
Cardenes, H. R.
Wagner, L.
Brell, J. M.
Ramanathan, R. K.
Crane, C. H.
Alberts, S. R.
Benson, A. B., III
机构：
[1] Indiana Univ, Eastern Cooperat Oncol Grp, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Northwestern Univ, Chicago, IL 60611 USA
[4] Case Western Reserve Univ, Cleveland, OH 44106 USA
[5] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[7] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.4506
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4506
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Quality of life study in patients with unresectable locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel versus gemcitabine alone:ax-panc-sy001: A phase II randomized study.
    Yalcin, Suayib
    Dane, Faysal
    Oksuzoglu, Berna
    Yildirim, Nuriye
    Isikdogan, Abdurrahman
    Ozkan, Metin
    Demirag, Guzin
    Coskun, Hasan Senol
    Karabulut, Bulent
    Evrensel, Turkkan
    Ustaoglu, Mehmet Ali
    Ozdemir, Feyyaz
    Turna, Hande
    Yavuzsen, Tugba
    Aykan, Faruk
    Sevinc, Alper
    Akbulut, Hakan
    Yuce, Deniz
    Hayran, Mutlu
    Kilickap, Saadettin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [42] Usefulness of Gemcitabine Therapy for Elderly Patients of Unresectable Pancreatic Cancer
    Katakura, Yoshiki
    Itoh, Fumio
    TUMOR BIOLOGY, 2008, 29 : 81 - 81
  • [43] Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study
    Roberto Petrioli
    Giandomenico Roviello
    Anna Ida Fiaschi
    Letizia Laera
    Daniele Marrelli
    Franco Roviello
    Edoardo Francini
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 683 - 690
  • [44] Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer
    Tabernero, Josep
    Chiorean, E. Gabriela
    Infante, Jeffrey R.
    Hingorani, Sunil R.
    Ganju, Vinod
    Weekes, Colin
    Scheithauer, Werner
    Ramanathan, Ramesh K.
    Goldstein, David
    Penenberg, Darryl N.
    Romano, Alfredo
    Ferrara, Stefano
    Von Hoff, Daniel D.
    ONCOLOGIST, 2015, 20 (02): : 143 - 150
  • [45] Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study
    Petrioli, Roberto
    Roviello, Giandomenico
    Fiaschi, Anna Ida
    Laera, Letizia
    Marrelli, Daniele
    Roviello, Franco
    Francini, Edoardo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (04) : 683 - 690
  • [46] Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials
    Ottaiano, Alessandro
    Capozzi, Monica
    De Divitiis, Chiara
    De Stefano, Alfonso
    Botti, Gerardo
    Avallone, Antonio
    Tafuto, Salvatore
    ACTA ONCOLOGICA, 2017, 56 (03) : 377 - 383
  • [47] Locally advanced unresectable pancreatic cancer: Induction chemoradio therapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial
    Barhoumi, M.
    Mornex, F.
    Bonnetain, F.
    Rougier, P.
    Mariette, C.
    Bouche, O.
    Bosset, J. -F.
    Aparicio, T.
    Mineur, L.
    Azzedine, A.
    Hammel, P.
    Butel, J.
    Stremsdoerfer, N.
    Maingon, P.
    Bedenne, L.
    Chauffert, B.
    CANCER RADIOTHERAPIE, 2011, 15 (03): : 182 - 191
  • [48] A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer
    Chao, Yee
    Wu, Chen-Yi
    Wang, Jack P.
    Lee, Rheun-Chuan
    Lee, Wei-Ping
    Li, Chung-Pin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (03) : 637 - 642
  • [49] Phase I study of veliparib with gemcitabine and radiation therapy in patients with borderline resectable and locally advanced unresectable pancreatic cancer.
    Tuli, Richard
    Nissen, Nicholas N.
    Annamalai, Alagappan
    Hoffman, David M. J.
    Bryant, Miranda
    Tighiouart, Mourad
    Rogatko, Andre
    Rokhsar, Sepehr
    Scher, Kevin S.
    Jamil, Laith
    Lo, Simon
    Hendifar, Andrew Eugene
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [50] Gemcitabine plus afatinib versus gemcitabine alone in metastatic pancreatic cancer: An explorative randomized AIO phase II trial (ACCEPT)
    Haas, M.
    Waldschmidt, D.
    Stahl, M.
    Reinacher-Schick, A.
    Freiberg-Richter, J.
    Kaiser, F.
    Kanzler, S.
    Frickhofen, N.
    Seufferlein, T.
    Dechow, T.
    Mahlberg, R. J. C.
    Malfertheiner, P.
    Illerhaus, G.
    Kubicka, S.
    Held, S.
    Westphalen, C. B.
    Kruger, S.
    Boeck, S.
    Heinemann, V.
    ANNALS OF ONCOLOGY, 2018, 29 : 243 - 243
12345